Dermapharm Holding SE Logo

Dermapharm Holding SE

Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.

DMP | F

Overview

Corporate Details

ISIN(s):
DE000A2GS5D8
LEI:
5299009F0KNZINQQQK37
Country:
Germany
Address:
Lil-Dagover-Ring 7, 82031 Grünwald
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dermapharm Holding SE is a manufacturer of patent-free branded pharmaceuticals and other healthcare products. Established in 1991, the company operates an integrated business model encompassing in-house research, development, production, and distribution. Its activities are primarily structured into two segments: "Branded pharmaceuticals and other healthcare products" and "Parallel import business." The company focuses on profitable, niche markets and implements a growth strategy that combines organic development with targeted acquisitions to expand its product portfolio and international footprint. Key assets include in-house R&D competence, a pipeline of development projects, and over 1,300 marketing authorizations for products such as over-the-counter medicines and herbal supplements.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Earnings Release
Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong…
English 24.7 KB
2025-11-13 00:00
Regulatory News Service
Q3 statement / Q3 financial report 2025
English 350.5 KB
2025-11-05 13:48
Report Publication Announcement
English 4.0 KB
2025-11-03 11:45
Director's Dealing
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
English 6.3 KB
2025-08-26 07:30
Earnings Release
Dermapharm confirms stable business development in H1 2025 and records EBITDA g…
English 25.4 KB
2025-08-26 00:00
Interim Report
Half-yearly financial report 2025
English 1.5 MB
2025-08-18 09:26
Report Publication Announcement
English 4.0 KB
2025-08-12 07:30
Earnings Release
Dermapharm Holding SE remains on projected growth trajectory in Q2 2025
English 15.1 KB
2025-07-04 16:18
Director's Dealing
Dermapharm Holding SE: Wilhelm Beier, buy
English 5.8 KB
2025-07-01 12:30
Declaration of Voting Results & Voting Rights Announcements
German 12.3 KB
2025-06-27 14:40
Declaration of Voting Results & Voting Rights Announcements
English 12.0 KB
2025-06-26 17:43
Post-Annual General Meeting Information
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of…
English 10.9 KB
2025-06-24 16:46
Director's Dealing
Dermapharm Holding SE: Dr. Andreas Eberhorn, buy
English 5.8 KB
2025-06-05 12:29
Director's Dealing
Dermapharm Holding SE: Anja Schorn, buy
English 6.2 KB
2025-06-04 11:19
Director's Dealing
Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
English 6.9 KB

Automate Your Workflow. Get a real-time feed of all Dermapharm Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dermapharm Holding SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Dermapharm Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-30 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 54,530,000.00 EUR
2024-12-30 Beier, Wilhelm Supervisory board Buy None 3,895,000.00 EUR
2024-11-15 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 6,464,000.00 EUR
2024-11-11 Feldmeier, Dr. Hans-Georg Board Buy None 95,185.00 EUR
2024-11-05 Dreibholz, Christof Board Buy None 27,720.00 EUR
2024-10-23 Lanz, Susanne Gertrud Pia Close relation Buy None 19,704.55 EUR
2024-08-29 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 29,954,600.00 EUR
2024-06-11 Lanz, Susanne Gertrud Pia Close relation Buy None 101,778.57 EUR
2024-05-22 Themis Beteiligungs-Aktiengesellschaft Close relation Buy None 8,577,500.00 EUR
2023-06-27 Feldmeier, Dr. Hans-Georg Board Buy None 99,902.36 EUR

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.